RARRES1

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RARRES1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RARRES1 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RARRES1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RARRES1 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and HNSC are the cancer types where RARRES1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PDACDFSMedianIII,IV0.6250.757.02111view →
CCRCCOSTertileAll0.3521.000.0106view →
HNSCOSMedianII,III,IV0.9351.000.0281view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RARRES1–PDAC (DFS)

Kaplan–Meier survival curve for RARRES1 mass-spec protein-high vs -low samples in PDAC.

Open the PDAC breakdown →

Exploration